SynthesisAntimicrobial resistance and infection control2018
A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States.
Synthesis in Antimicrobial resistance and infection control, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 108 citations in OpenAlex.
- Developing Regionally Coordinated Infection Control Strategies for Carbapenem-Resistant and Carbapenemase-Producing Enterobacterales in Acute and Long-Term Care Hospitals: A Delphi Study.Journal of Korean medical science · 2026Article
- Detection of New Delhi metallo-β-lactamase (blaScientific reports · 2026Article
- Recurrence, Readmission, and Key Mortality Predictors in Patients with Carbapenem-Resistant Enterobacterales Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Analysis of risk factors for mortality from carbapenem-resistantTranslational pediatrics · 2025Article
- Amoxicillin conjugated functionalized zinc ferrite nanoparticles for enhanced antibacterial, antibiofilm, and antioxidant activities.Scientific reports · 2025Article
- Fecal carriage and molecular characterization of carbapenem-resistantFrontiers in microbiology · 2025Article
- Characterization of carbapenem-resistant Enterobacterales andJournal of clinical microbiology · 2024Article
- Clonal and horizontal transmission of carbapenem-resistant Enterobacterales strains and genes via flies.Gut pathogens · 2024Article
- An Overview of the Recent Advances in Antimicrobial Resistance.Microorganisms · 2024Review
- Freshwater and Marine Environments in California Are a Reservoir of Carbapenem-Resistant Bacteria.Microorganisms · 2024Article
- Facility- and patient-level factors associated with implementation of contact precautions in hospitalized VA patients with positive CRE cultures.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Epidemiology of carbapenem-resistant organisms in Alameda County, California, 2019-2021.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Skin secretions of Leptodactylidae (Anura) and their potential applications.The journal of venomous animals and toxins including tropical diseases · 2024Review
- Epidemiological Characteristics of Carbapenem-ResistantPathogens (Basel, Switzerland) · 2023Article
- Characterization of Carbapenemase- and ESBL-Producing Gram-Negative Bacilli Isolated from Patients with Urinary Tract and Bloodstream Infections.Antibiotics (Basel, Switzerland) · 2023Article
- Uptake in newly approved antibiotics prescribed to patients with carbapenem-resistant Enterobacterales (CRE).Infection control and hospital epidemiology · 2023Article
- Article
- Transmission of Carbapenem-Resistant Klebsiella pneumoniae in US Hospitals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Analysis on Bacterial Distribution and Change of Drug Resistance Rate in ICUs Across Southwest China from 2018 to 2022.Infection and drug resistance · 2023Article
- Predominance of OXA-48 Carbapenemase-Producing Enterobacterales in a Moroccan Hospital.International journal of microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Enterobacteriaceae (CRE) pose an urgent public health threat in the United States. An important step in planning and monitoring a national response to CRE is understanding its epidemiology and associated outcomes. We conducted a systematic literature review of studies that investigated incidence and outcomes of CRE infection in the US. Methods: We performed searches in MEDLINE via Ovid, CDSR, DARE, CENTRAL, NHS EED, Scopus, and Web of Science for articles published from 1/1/2000 to 2/1/2016 about the incidence and outcomes of CRE at US sites. Results: Five studies evaluated incidence, but many used differing definitions for cases. Across the entire US population, the reported incidence of CRE was 0.3-2.93 infections per 100,000 person-years. Infection rates were highest in long-term acute-care (LTAC) hospitals. There was insufficient data to assess trends in infection rates over time. Four studies evaluated outcomes. Mortality was higher in CRE patients in some but not all studies. Conclusion: While the incidence of CRE infections in the United States remains low on a national level, the incidence is highest in LTACs. Studies assessing outcomes in CRE-infected patients are limited in number, small in size, and have reached conflicting results. Future research should measure a variety of clinical outcomes and adequately adjust for confounders to better assess the full burden of CRE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.